RxDoctor Payments Data

Jodi Herche

Psychiatric/Mental Health · Columbus, INNPI 1184348377

Payments from drug & device makers

$2,957in general payments, 2019–2025

Across 170 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$629
  • Supernus Pharmaceuticals, Inc.$415
  • Lilly USA, LLC$288
  • Corium, LLC$251
  • Vanda Pharmaceuticals Inc.$211
  • Novo Nordisk$186
  • plus $977 from 21 others

What the payments were for

  • Food & beverage$2,92799%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,957 in reported general payments places this provider in the 80th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$20,056
Medicare patients
74
Services billed
230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole42$68,929
VraylarCariprazine Hcl30$68,076
CaplytaLumateperone Tosylate40$67,035
TrintellixVortioxetine Hydrobromide75$54,056
Invega SustennaPaliperidone Palmitate13$42,960
Aripiprazole69$6,371
Desvenlafaxine Succinate ErDesvenlafaxine Succinate53$5,763
Quetiapine Fumarate ErQuetiapine Fumarate41$5,332
Atomoxetine Hcl19$3,112
Ramelteon14$2,028
Olanzapine40$1,815
Mirtazapine55$1,598
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine21$1,442
Buspirone Hcl55$1,395
Duloxetine Hcl54$1,205

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$65$68,92942 claims
AbbVieVraylar$629$68,07630 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$110$67,03540 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$56$54,05675 claims
Johnson & JohnsonInvega Sustenna$53$42,96013 claims
Lilly USA, LLCOlanzapine$288$1,81540 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in Columbus

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →